Oral hormone replacement therapy does increase the risk of blood clots, roughly doubling the odds of venous thromboembolism compared with not using it. But that headline number obscures what matters most: the risk depends heavily on how the estrogen is delivered, which type of estrogen is used, which progestin accompanies it, and what personal risk factors you bring to the table. Transdermal patches and vaginal preparations tell a very different story from pills, and newer hormone formulations carry less risk than older ones.
Why the Route of Delivery Changes Everything
When you swallow an estrogen pill, it passes through the liver before reaching the rest of your body. That first pass through the liver is the core problem. The liver responds to the concentrated estrogen by ramping up production of clotting proteins and dialing down some of the body’s natural anticoagulant defenses. In animal studies, oral ethinylestradiol dose-dependently altered levels of several coagulation factors in the liver, increasing some clotting factors while decreasing antithrombin, one of the body’s key clot-preventing proteins.1Journal of Thrombosis and Haemostasis. 17α‐Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor α In human studies, oral estrogen significantly increased markers of clotting activation and decreased antithrombin activity compared with no treatment.2PubMed. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women
Transdermal estrogen, delivered through a skin patch or gel, bypasses the liver entirely. It enters the bloodstream directly through the skin, so the liver never sees that initial flood of concentrated hormone. The result is that transdermal preparations have minimal effects on clotting proteins. A meta-analysis pooling data from multiple studies found that oral estrogen users had about 1.9 times the risk of venous thromboembolism compared with nonusers, while transdermal estrogen users showed no increased risk at all, with a pooled risk ratio of 1.0.3PubMed. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women That is not a modest difference. Oral roughly doubles the risk; transdermal appears to add no risk whatsoever.
The clot risk with oral HRT tends to be highest in the first few months of use and then levels off, though it does not disappear.4PubMed Central. Estrogen and thrombosis: A bench to bedside review This early spike is consistent with what clinicians see with other estrogen-containing medications, including birth control pills. The body’s clotting system is most disrupted during the initial adjustment period.
Not All Estrogens Are Created Equal
Even among oral formulations, there are meaningful differences depending on which estrogen you take. The two main options are conjugated equine estrogens (derived from horse urine, sold under brand names like Premarin) and estradiol (a bioidentical hormone that matches what the human body naturally produces). A large study using UK medical records covering hundreds of thousands of women found that estradiol-only pills were associated with about a 15% lower clot risk than conjugated equine estrogen pills. For combination pills containing a progestin, estradiol-based formulations carried about a 17% lower risk than those using conjugated equine estrogens.5BMJ. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
A separate study comparing the two estrogen types head-to-head found an even starker difference: current users of oral conjugated equine estrogens had roughly twice the odds of venous thrombosis compared with current users of oral estradiol. The conjugated equine estrogen users also showed stronger laboratory markers of clotting tendency, with higher thrombin generation and greater resistance to one of the body’s natural anticoagulant pathways.6JAMA Internal Medicine. Lower Risk of Cardiovascular Events in Postmenopausal Women Taking Oral Estradiol Compared With Oral Conjugated Equine Estrogens
The practical upshot is that if oral HRT is chosen, estradiol-based formulations appear safer from a clotting standpoint than conjugated equine estrogens. This distinction was not widely appreciated during the era of the Women’s Health Initiative trial, which used conjugated equine estrogens exclusively and produced the alarming blood clot findings that made headlines in the early 2000s.
The Progestin Matters Too
Women who still have a uterus need a progestin alongside estrogen to protect the uterine lining. But the type of progestin chosen has its own effect on clot risk. Medroxyprogesterone acetate (MPA), a synthetic progestin that was the standard pairing in older HRT regimens, has been linked to substantially higher clot risk than micronized progesterone, which is bioidentical to what the body naturally produces.7PubMed Central. Hormonal therapies and venous thrombosis: Considerations for prevention and management
Real-world data bears this out. A study comparing the two most common combination regimens found that women taking oral estradiol with micronized progesterone had significantly fewer clot events than women taking oral conjugated equine estrogens with medroxyprogesterone acetate, with roughly 37 versus 53 clot events per 10,000 women per year.8PubMed. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice That combination of estradiol plus micronized progesterone represents the direction most menopause specialists have moved in recent years, partly because of these clotting data and partly because micronized progesterone is better tolerated in other ways.
For perspective, clinical guidance generally holds that progestogens of either type can be used safely in most patients, and that the bigger lever for reducing clot risk is the route of estrogen delivery rather than which progestin accompanies it.9PubMed Central. Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias Still, when both levers can be pulled, choosing estradiol over conjugated equine estrogens and micronized progesterone over MPA stacks the odds more favorably.
Who Faces the Highest Risk
Some women walk into an HRT prescription with preexisting risk factors that multiply the danger of oral estrogen. Two of the most studied are inherited clotting mutations and obesity.
Factor V Leiden is the most common inherited clotting disorder, carried by around 5% of people of European descent. A study of a British-South Asian cohort found that women carrying a Factor V Leiden mutation who were prescribed estrogen had more than double the rate of venous thromboembolism compared with estrogen users without the mutation. The interaction became more dramatic when other health conditions were present: among women with the mutation who also had two other medical conditions, nearly one in five experienced a clot.10PubMed Central. Factor V Leiden, estrogen, and multimorbidity association with venous thromboembolism in a British-South Asian cohort For those with three other conditions, the figure rose to about 29%.
Obesity compounds oral estrogen’s clotting risk in a similarly dramatic way. In the ESTHER study, a French case-control study of postmenopausal women, the combination of oral estrogen use and obesity resulted in roughly 20 times the clot risk compared with normal-weight women not using estrogen. Overweight women on oral estrogen faced about 10 times the risk. The encouraging finding, consistent with everything else in this article, was that women with increased body weight who used transdermal estrogen had a similar risk to overweight women not using estrogen at all. The patch effectively neutralized the additive danger.11Journal of Thrombosis and Haemostasis. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration
These findings underline why a one-size-fits-all approach to HRT is outdated. A thin, healthy woman with no family history of clots taking a transdermal estradiol patch faces a very different risk profile from an obese woman with a Factor V Leiden mutation taking oral conjugated equine estrogens. The same drug class, wildly different outcomes.
Vaginal Estrogen Is a Category Apart
Vaginal estrogen preparations, typically low-dose creams, rings, or tablets used for urogenital symptoms like dryness and urinary discomfort, deliver estrogen locally with very little entering the general circulation. For this reason, they have generally been considered safe from a clotting standpoint even for women who cannot take systemic HRT.
A nested case-control study of women with a history of venous thromboembolism, the exact population you would worry about most, found that vaginal estradiol use was not associated with recurrent blood clots. Current users showed no statistically significant increase in risk.12PubMed. Recurrent venous thromboembolism and vaginal estradiol in women with prior venous thromboembolism: A nested case-control study This is reassuring because urogenital symptoms of menopause can be severe and debilitating, and many women with clotting histories have been told to avoid all forms of estrogen. For these women, vaginal estrogen remains a viable option that clinical guidelines generally support.
HRT and Stroke
Blood clots in the veins (deep vein thrombosis and pulmonary embolism) get most of the attention in HRT discussions, but arterial clots, which cause strokes and heart attacks, are also part of the picture. The Women’s Health Initiative hormone trials, the largest randomized HRT studies ever conducted, identified a 44% increase in ischemic stroke risk with combination estrogen plus progestin and a 39% increase with estrogen alone.13Women’s Health Initiative. W6 – HT CVD Biomarkers: study of CHD, Stroke and VTE – Phase I
These numbers, again, came from trials using oral conjugated equine estrogens. Subsequent research suggests the oral-versus-transdermal distinction that matters so much for venous clots also applies to stroke. Available evidence indicates that ischemic stroke risk increases with oral HRT but not with transdermal delivery, and that timing relative to menopause may also matter. Women who begin HRT within about five years of menopause appear to fare better on stroke risk than those who start it later. Vaginal estrogen, interestingly, has been linked to a decreased stroke risk in observational data, though this could partly reflect the generally healthier population that uses it.
The stroke findings add another reason to favor transdermal delivery for women who need systemic hormone therapy, especially those with additional cardiovascular risk factors like high blood pressure or diabetes.
Gender-Affirming Hormone Therapy
Transgender women and other people assigned male at birth who use feminizing estrogen therapy face a related but distinct set of clotting concerns. The estrogen doses used for gender-affirming therapy are sometimes higher than those used for menopausal HRT, and the treatment typically continues for decades rather than years. A meta-analysis of 18 studies covering more than 11,500 transgender women on feminizing hormone therapy found a pooled venous thromboembolism prevalence of about 2%, with longer duration of estrogen use and older age both significantly associated with higher risk.14PubMed Central. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study
Transgender women using estrogen appear to be at increased risk of both arterial and venous thrombosis, and that risk may grow with longer time on treatment.15PubMed. Thrombotic risk associated with gender-affirming hormone therapy However, results are not uniform. A smaller Canadian cohort study documented no clot events at all among its transgender participants on hormone therapy.16Blood. Venous Thromboembolism in Transgender Individuals Receiving Hormone Replacement Therapy in Alberta, Canada The heterogeneity across studies likely reflects differences in estrogen type, dose, route, and patient demographics.
Clinical guidance for gender-affirming therapy mirrors the principles from postmenopausal HRT: transdermal estradiol is preferred over oral formulations, especially for individuals with additional clotting risk factors, and individualized risk assessment is recommended.9PubMed Central. Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias Much of the early data on transgender clotting risk came from an era when ethinylestradiol, a potent synthetic estrogen, was commonly used. Modern gender-affirming protocols have largely moved away from that formulation, and the risk profile with current regimens is expected to be lower, though long-term data are still accumulating.
What If You Already Have a Clotting History
A personal history of blood clots is often treated as a blanket contraindication to HRT, and oral HRT does indeed carry a strong warning for this group.17PubMed Central. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms But the evidence increasingly suggests that transdermal and vaginal estrogen can be used cautiously in women with prior clots, under medical supervision.
A study tracking recurrent clot events in postmenopausal women found a stark split by route: oral estrogen users had more than six times the risk of a recurrent clot compared with women not using hormones, while transdermal estrogen users showed no increased risk of recurrence at all.18PubMed Central. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women The meta-analytic data on transdermal estrogen in women with prior clots tells a consistent story: no excess risk of recurrence.3PubMed. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women
This does not mean anyone with a clotting history should start a patch without medical guidance. It does mean that the conversation with your doctor should be more nuanced than a flat “no hormones ever.” For women with severe hot flashes or other debilitating menopause symptoms who also carry a clotting history, a transdermal estradiol patch with micronized progesterone (if needed for uterine protection) represents the lowest-risk systemic option supported by current evidence. For those whose primary complaints are vaginal, low-dose vaginal estrogen may be appropriate even without systemic therapy.
For women who truly cannot use any form of estrogen, or who prefer to avoid it, nonhormonal alternatives for hot flashes do exist. These include certain antidepressants, gabapentin, and the newer drug fezolinetant, which was specifically developed for vasomotor symptoms in women who cannot take hormones. These options are worth discussing with a clinician rather than simply suffering through symptoms out of fear of clots that a transdermal formulation might not actually cause.
Why the Original HRT Scare Was Partly a Formulation Problem
The public fear of HRT and blood clots traces almost entirely to the Women’s Health Initiative, which reported its results beginning in 2002. Those trials used one specific regimen: oral conjugated equine estrogens, with or without medroxyprogesterone acetate. That combination now appears to be among the highest-risk HRT formulations available. It uses the estrogen type most strongly associated with clotting, delivered orally through the liver, combined with the progestin that carries the most clot risk.
Subsequent research has shown that switching to estradiol lowers clot risk by about 15 to 17% compared with conjugated equine estrogens when taken orally.5BMJ. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases Switching from oral to transdermal delivery appears to eliminate the excess risk entirely.3PubMed. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women And replacing medroxyprogesterone acetate with micronized progesterone lowers the combined regimen’s clot rate further.8PubMed. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice Stack all three changes together, and you go from the WHI’s concerning findings to a risk profile that looks dramatically different.
None of this means HRT is risk-free or appropriate for everyone. But a woman in 2024 being told she cannot consider any form of HRT because of the clot findings from a 2002 trial that used an older, riskier formulation is getting incomplete advice. The conversation should be about which HRT, not whether HRT, for the vast majority of symptomatic menopausal women without major contraindications.